<DOC>
	<DOCNO>NCT02838342</DOCNO>
	<brief_summary>This study evaluate potential immunomodulatory synergy association metronomic cyclophosphamide ( CMC ) interferon-alpha ( IFN-alpha ) .</brief_summary>
	<brief_title>Pharmaco-immunological Study Interferon-alpha Metronomic Cyclophosphamide Association Neuroendocrine Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>performance status ECOGWHO â‰¤ 1 histologically proved neuroendocrine tumor Ki67 &lt; = 10 % , metastatic locally advance without surgery possibility least one measurable lesion base RECIST criterion version 1.1 sign write informed consent previous treatment interferon cyclophosphamide treatment immunosuppressive drug diabetes complicate coronary artery disease vasculopathy severe respiratory failure , chronic respiratory failure , COPD history severe heart failure severe renal hepatic impairment diabetes complicate coronary artery disease vasculopathy alcoholism unweaned uncontrolled epilepsy and/or achievement central nervous system function history severe depressive syndrome presence history severe psychiatric condition , particularly severe depression , suicidal thought attempt suicide decompensated liver cirrhosis severe myelosuppression psoriasis sarcoidosis active disease condition uncontrolled infection association yellow fever vaccine association phenytoin prophylaxis hypersensitivity interferon cyclophosphamide prior history malignancy except : basal cell carcinoma skin , cervical intraepithelial neoplasia cancer curatively treat evidence disease least 3 year pregnancy , breastfeed absence adequate contraception fertile patient patient guardianship , curatorship protection justice</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>